SAMIR EZZELDIN WITTA
Pilots at Orch Dr, Englewood, CO
License number
Colorado A4673210
Issued Date
Jun 2015
Expiration Date
Jun 2017
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
9622 E Orchard Dr, Englewood, CO 80111
Professional information
Gefitnib Sensitivity-Related Gene Expression And Products And Methods Related Thereto
US Patent:
2012017, Jul 12, 2012
Filed:
Mar 12, 2012
Appl. No.:
13/418004
Inventors:
Paul A. BUNN - Evergreen CO, US
Christopher D. COLDREN - Denver CO, US
Wilbur A. FRANKLIN - Denver CO, US
Mark W. GERACI - Aurora CO, US
Barbara A. HELFRICH - Lakewood CO, US
Fred R. HIRSCH - Denver CO, US
Razvan LAPADAT - Denver CO, US
Michio SUGITA - Centennial CO, US
Samir E. WITTA - Greenwood Village CO, US
Christopher D. COLDREN - Denver CO, US
Wilbur A. FRANKLIN - Denver CO, US
Mark W. GERACI - Aurora CO, US
Barbara A. HELFRICH - Lakewood CO, US
Fred R. HIRSCH - Denver CO, US
Razvan LAPADAT - Denver CO, US
Michio SUGITA - Centennial CO, US
Samir E. WITTA - Greenwood Village CO, US
International Classification:
A61K 39/395, A61K 31/517, A61P 35/00, C40B 30/00, G01N 33/566, G01N 21/64, G01N 21/76, G01N 27/62, A61K 31/5377, C12Q 1/02
US Classification:
4241331, 4241421, 5142345, 5142664, 435 29, 435 723, 506 7
Abstract:
Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.
Gefitinib Sensitivity-Related Gene Expression And Products And Methods Related Thereto
US Patent:
2007027, Nov 22, 2007
Filed:
Jan 24, 2005
Appl. No.:
10/587052
Inventors:
Paul Bunn Jr. - Evergreen CO, US
Christopher Coldren - Denver CO, US
Wilbur Franklin - Denver CO, US
Mark Geraci - Aurora CO, US
Barbara Helfrich - Lakewood CO, US
Fred Hirsch - Denver CO, US
Razvan Lapadat - Denver CO, US
Michio Sugita - Centennial CO, US
Samir Witta - Greenwood Village CO, US
Christopher Coldren - Denver CO, US
Wilbur Franklin - Denver CO, US
Mark Geraci - Aurora CO, US
Barbara Helfrich - Lakewood CO, US
Fred Hirsch - Denver CO, US
Razvan Lapadat - Denver CO, US
Michio Sugita - Centennial CO, US
Samir Witta - Greenwood Village CO, US
Assignee:
The Regents of the University of Colorado - Boulder CO
International Classification:
A61K 31/00, A61P 35/00, C12Q 1/02, C12Q 1/68
US Classification:
514789000, 435029000, 435006000
Abstract:
Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to gefitinib and other EGFR inhibitors, and products and processes related thereto. Specifically, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for the detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.
Gefitinib Sensitivity-Related Gene Expression And Products And Methods Related Thereto
US Patent:
2008011, May 15, 2008
Filed:
Jul 23, 2007
Appl. No.:
11/781946
Inventors:
Paul A. BUNN - Steamboat Springs CO, US
Christopher D. COLDREN - Denver CO, US
Wilbur A. FRANKLIN - Denver CO, US
Mark W. GERACI - Aurora CO, US
Barbara A. HELFRICH - Lakewood CO, US
Fred R. HIRSCH - Denver CO, US
Razvan LAPADAT - Indianapolis IN, US
Michio SUGITA - Centennial CO, US
Samir E. WITTA - Greenwood Village CO, US
Christopher D. COLDREN - Denver CO, US
Wilbur A. FRANKLIN - Denver CO, US
Mark W. GERACI - Aurora CO, US
Barbara A. HELFRICH - Lakewood CO, US
Fred R. HIRSCH - Denver CO, US
Razvan LAPADAT - Indianapolis IN, US
Michio SUGITA - Centennial CO, US
Samir E. WITTA - Greenwood Village CO, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO - Boulder CO
International Classification:
C40B 30/04, G01N 33/574, C12Q 1/68
US Classification:
506 9, 435 723, 435 6
Abstract:
Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.
Gefitnib Sensitivity-Related Gene Expression And Products And Methods Related Thereto
US Patent:
2010019, Aug 5, 2010
Filed:
Jul 23, 2008
Appl. No.:
12/670052
Inventors:
Paul A. Bunn - Evergreen CO, US
Christopher D. Coldren - Denver CO, US
Wilbur A. Franklin - Denver CO, US
Mark W. Geraci - Aurora CO, US
Barbara A. Helfrich - Lakewood CO, US
Fred R. Hirsch - Denver CO, US
Razvan Lapadat - Denver CO, US
Michio Sugita - Centennial CO, US
Samir E. Witta - Greenwood Village CO, US
Christopher D. Coldren - Denver CO, US
Wilbur A. Franklin - Denver CO, US
Mark W. Geraci - Aurora CO, US
Barbara A. Helfrich - Lakewood CO, US
Fred R. Hirsch - Denver CO, US
Razvan Lapadat - Denver CO, US
Michio Sugita - Centennial CO, US
Samir E. Witta - Greenwood Village CO, US
International Classification:
A61K 39/395, C12Q 1/68, A61K 31/5377, A61K 31/517, A61K 31/497
US Classification:
4241331, 435 6, 5142345, 5142664, 51425218, 4241411
Abstract:
Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.
Histone Deacetylase Inhibitors Sensitize Cancer Cells To Epidermal Growth Factor Inhibitors
US Patent:
2012014, Jun 7, 2012
Filed:
Jul 23, 2008
Appl. No.:
12/670053
Inventors:
Samir E. Witta - Greenwood Village CO, US
Paul A. Bunn - Evergreen CO, US
Harry A. Drabkin - Denver CO, US
Robert M. Gemmill - Centennial CO, US
Daniel Chan - Denver CO, US
Paul A. Bunn - Evergreen CO, US
Harry A. Drabkin - Denver CO, US
Robert M. Gemmill - Centennial CO, US
Daniel Chan - Denver CO, US
International Classification:
A61K 39/395, A61P 35/00, A61K 31/404, A61K 31/343, A61K 31/496, A61K 31/517, A61K 31/4406, A61K 38/12
US Classification:
4241341, 514357, 514 199, 514469, 51425218, 51426624, 514414, 4241741, 4241331, 514 194
Abstract:
Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity.
Histone Deacetylase Inhibitors Sensitize Cancer Cells To Epidermal Growth Factor Inhibitors
US Patent:
2008018, Jul 31, 2008
Filed:
Sep 25, 2007
Appl. No.:
11/861033
Inventors:
Samir E. Witta - Greenwood Village CO, US
Paul A. Bunn - Steamboat Springs CO, US
Harry A. Drabkin - Charleston SC, US
Robert M. Gemmill - Charleston SC, US
Daniel Chuen-Fong Chan - Denver CO, US
Paul A. Bunn - Steamboat Springs CO, US
Harry A. Drabkin - Charleston SC, US
Robert M. Gemmill - Charleston SC, US
Daniel Chuen-Fong Chan - Denver CO, US
International Classification:
A61K 31/498, A61K 31/4406
US Classification:
51426624, 514357
Abstract:
Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity.
Method Of Using Saha And Erlotinib For Treating Cancer
US Patent:
2008022, Sep 11, 2008
Filed:
May 2, 2008
Appl. No.:
12/150999
Inventors:
Paul Bunn - Evergreen CO, US
Samir Witta - Greenwood Village CO, US
Victoria M. Richon - Wellesley MA, US
Stanley R. Frankel - Yardley PA, US
Paul J. Deutsch - Princeton NJ, US
Sophia Randolph - Burien WA, US
Samir Witta - Greenwood Village CO, US
Victoria M. Richon - Wellesley MA, US
Stanley R. Frankel - Yardley PA, US
Paul J. Deutsch - Princeton NJ, US
Sophia Randolph - Burien WA, US
International Classification:
A61K 31/517, A61P 35/00
US Classification:
5142664
Abstract:
The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Erlotinib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.
Histone Deacetylase Inhibitors Sensitize Cancer Cells To Epidermal Growth Factor Inhibitors
US Patent:
2008023, Sep 25, 2008
Filed:
Mar 13, 2006
Appl. No.:
11/908388
Inventors:
Samir E. Witta - Greenwood Village CO, US
Paul A. Bunn - Steamboat Springs CO, US
Harry A. Drabkin - Charleston SC, US
Robert M. Gemmill - Charleston SC, US
Daniel Chuen-Fong Chan - Denver CO, US
Paul A. Bunn - Steamboat Springs CO, US
Harry A. Drabkin - Charleston SC, US
Robert M. Gemmill - Charleston SC, US
Daniel Chuen-Fong Chan - Denver CO, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO - Denver CO
International Classification:
A61K 31/16, A61K 31/19, A61K 31/27, A61K 31/395, A61K 31/5377, A61K 31/517, C12Q 1/68
US Classification:
5142345, 514575, 514557, 514487, 514183, 5142664, 435 6
Abstract:
Disclosed is the use of a combination of histone deacetylase inhibitors and epidermal growth factor receptor (EGFR) inhibitors to treat cancer.
Markers For Assessing The Susceptibility Of Cancer To Igf-1R Treatment
US Patent:
2011026, Oct 27, 2011
Filed:
Aug 20, 2009
Appl. No.:
13/059931
Inventors:
Samir E. Witta - Greenwood Village CO, US
Koichi Yoshida - Tokyo, JP
Rafal Dziadziuszko - Gdarisk, PL
Fred R. Hirsch - Denver CO, US
Koichi Yoshida - Tokyo, JP
Rafal Dziadziuszko - Gdarisk, PL
Fred R. Hirsch - Denver CO, US
International Classification:
A61K 39/395, A61P 35/00, A61K 38/45, C12Q 1/02
US Classification:
4241581, 435 29, 424 945
Abstract:
The present invention relates to a method of predicting response of a cancer cell tissue to IGF-IR treatment. The inventors have observed a direct relationship between the expression of survivin, ErbB and E-cadherin and the response of cancer cells to IGF-IR treatment. This observation permits screening of tumor cells prior to treatment to determine whether the cancer will respond to IGF-IR treatment, and/or to monitor the efficacy of such a treatment by conducting “before and after” assessments of the expression of these markers